MABPHARM LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.395 HKD | 0.00% |
|
+8.22% | -14.13% |
| 03:17pm | Mabpharm's New Drug Application Gets Peru's Regulator's Approval | MT |
| 06-26 | Simcere Zaiming and Mabpharm Limited Announce Approval of Cetuximab Beta in China by the NMPA | CI |
Mabpharm Ltd is China-based company mainly engaged in the research, development and production of monoclonal antibody drugs for cancers and autoimmune diseases. The Company's main products include omalizumab (CMAB007), cetuximab (CMAB009) and infliximab (CMAB008). The Company mainly conducts its businesses in China market.
Calendar
2024-08-22
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -14.13% | 209M | |
| +17.24% | 122B | |
| +18.36% | 114B | |
| +19.62% | 25.71B | |
| -25.48% | 19.02B | |
| -20.21% | 15.83B | |
| -19.55% | 15.32B | |
| -47.37% | 14.88B | |
| +61.57% | 14.82B | |
| +5.21% | 14.1B |
- Stock Market
- Equities
- 2181 Stock
- News Mabpharm Limited
- China Gives New Drug Application Approval to Mabpharm's Anti-Asthma Therapy
